Micromotors Deliver Oral Vaccines
Researchers used magnesium particles as tiny motors to deliver an oral vaccine against the bacterial pathogen Staphylococcus aureus.
Scientists are trying to develop oral vaccines for infectious diseases to aid patient adherence. To be effective, the vaccine must survive digestion and reach immune cells within the intestinal wall. Researchers reporting in the American Chemical Society (ACS) journal Nano Letters have developed oral vaccines powered by micromotors that target the mucus layer of the intestine.
In the study published on Feb. 6, 2019, researchers explored whether magnesium particles could be used as tiny motors to deliver an oral vaccine against the bacterial pathogen Staphylococcus aureus. When coated over most of their surfaces with titanium dioxide, magnesium microparticles use water as fuel to generate hydrogen bubbles that power their propulsion.
To develop the oral vaccine, the researchers coated magnesium micromotors with red blood cell membranes that displayed the Staphylococcal α-toxin, along with a layer of chitosan to help them stick to the intestinal mucus. Then they added an enteric coating that protects drugs from the acidic conditions of the stomach. When given orally to mice, the micromotors safely passed through the stomach, and then the enteric coating dissolved, activating the motors. Imaging of mice that had been given the vaccine showed that the micromotors accumulated in the intestinal wall much better than non-motorized particles.
In addition to avoiding needles, ACS states that oral vaccines can generate a broader immune response by stimulating immune cells within the mucus layer of the intestine to produce a special class of antibody called immunoglobulin A (IgA). The micromotors in the study also stimulated the production of about ten times more IgA antibodies against the Staphylococcal α-toxin than the static particles.
The study was funded by the Defense Threat Reduction Agency Joint Science and Technology Office for Chemical and Biological Defense, the National Council of Science and Technology in Mexico, the Charles Lee Powell Foundation, and the National Cancer Institute.
Source: ACS
Texas' MD Anderson Cancer Center Creates New Cell Therapy Institute
November 11th 2024With the launch of the Institute for Cell Therapy Discovery and Innovation, the MD Anderson Cancer Center will bring together expertise in developing cell therapies for cancer, autoimmune diseases, and infections.
